Difference between revisions of "Dabrafenib (Tafinlar)"
m |
|||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| + | *[[Non-small cell lung cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 15: | Line 16: | ||
*5/29/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm FDA approved] "for the treatment of patients with unresectable or metastatic [[Melanoma | melanoma with BRAF V600E mutation]] as detected by an FDA-approved test."<ref name="insert"></ref> | *5/29/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm FDA approved] "for the treatment of patients with unresectable or metastatic [[Melanoma | melanoma with BRAF V600E mutation]] as detected by an FDA-approved test."<ref name="insert"></ref> | ||
*1/10/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm381159.htm FDA approved] to be used together with [[Trametinib (Mekinist)]] "for the treatment of patients with unresectable or metastatic [[melanoma]] with BRAF V600E or V600K mutations as detected by an FDA-approved test." | *1/10/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm381159.htm FDA approved] to be used together with [[Trametinib (Mekinist)]] "for the treatment of patients with unresectable or metastatic [[melanoma]] with BRAF V600E or V600K mutations as detected by an FDA-approved test." | ||
| + | *6/22/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm FDA approved] in combination with [[Trametinib (Mekinist)]] "for patients with metastatic [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] with BRAF V600E mutation as detected by an FDA-approved test." | ||
==Also known as== | ==Also known as== | ||
| Line 30: | Line 32: | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Drugs FDA approved in 2013]] | [[Category:Drugs FDA approved in 2013]] | ||
Revision as of 01:12, 23 June 2017
General information
Class/mechanism: BRAF kinase inhibitor. Dabrafenib inhibits some mutated BRAF kinases, such as BRAF V600E, BRAF V600K, and BRAF V600D. Some BRAF mutations such as BRAF V600E cause constitutive activation of the BRAF pathway, which drives tumor cell growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 5/29/2013: FDA approved "for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test."[1]
- 1/10/2014: FDA approved to be used together with Trametinib (Mekinist) "for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test."
- 6/22/2017: FDA approved in combination with Trametinib (Mekinist) "for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test."
Also known as
- C23H20F3N5O2S2•CH4O3S, Dabrafenib mesylate, GSK2118436, GSK-2118436A, N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt.